Aspirin and levofloxacin for the prevention of the occurrence of prostate cancer or transformation to castration-resistant prostate cancer: a two-part, open-label, randomised, controlled study

@article{Yang2016AspirinAL,
  title={Aspirin and levofloxacin for the prevention of the occurrence of prostate cancer or transformation to castration-resistant prostate cancer: a two-part, open-label, randomised, controlled study},
  author={L. Yang and Yong-ji Chen and Z. Tang and Wenbin Xue and S. Qiu and P. Tan and Q. Wei},
  journal={The Lancet},
  year={2016},
  volume={388}
}
BACKGROUND The role that inflammation plays in the development of prostate cancer is unknown. We aimed to assess whether an anti-inflammatory drug or antibiotic, or both, could prevent prostate cancer occurrence and delay transformation to castration-resistant prostate cancer. METHODS This open-label, randomised, controlled trial recruited participants who had undergone a prostate biopsy in West China Hospital of Sichuan University. Participants older than 40 years pathologically confirmed… Expand
2 Citations